Late-Day Spike! Multiple Sci-Tech Board Stocks Show Abnormal Bidding Activity, Brain-Computer Interface Concept Rallies

Multiple Sci-Tech Innovation Board stocks exhibited unusual bidding activity at the close.

Today (March 13), the Shanghai Composite Index fluctuated downward during the trading session, losing the 4,100-point mark at the close; Hong Kong stocks also weakened, with the Hang Seng Index and Hang Seng Tech Index both falling nearly 1%.

Specifically, the Shanghai Composite Index oscillated and declined during the day, accelerating in the afternoon, and closed below 4,100 points. By the end of the day, it fell 0.81% to 4,095.45 points. The Shenzhen Component Index dropped 0.65%, the ChiNext Index declined 0.22%, and the Sci-Tech Innovation Board Composite Index decreased 1.44%. The combined turnover of the Shanghai and Shenzhen markets was approximately 24.2 trillion yuan, about 430 billion yuan less than the previous day.

Over 3,800 A-share stocks were in the red, with declines in sectors such as power, non-ferrous metals, chemical fibers, and semiconductors. Computing power concepts collectively retreated, with UCloud, Hand Enterprise, and others dropping over 10%. The chemical industry remained strong, with Jinniu Chemical hitting the daily limit-up again, achieving 6 limit-ups in the past 10 trading days. Fertilizer concepts performed well, with Luxin Technology hitting two consecutive limit-ups, and ChuanJinNuo surging nearly 15%. Heat pump concepts rose, with Sunrise Oriental and Vanward Electric hitting the daily limit-up. Brain-computer interface concepts surged in the afternoon, with Yingkang Life up over 12%, and Sanbo Brain Science once rising over 12%. Notably, Huagong Technology declined again, with a total daily turnover of 19.45 billion yuan, ranking first in A-share trading volume.

Multiple Sci-Tech Innovation Board stocks experienced unusual bidding activity

At the close today, many Sci-Tech Innovation Board stocks suddenly moved sharply. Baichu Electronics, Efort, Stone Technology, and DJI drones surged, while Cambrian, China Science and Technology Star Map, China Science and Technology Fei Testing, and Rejing Biological fell rapidly.

On the news front, the Shanghai Stock Exchange and China Securities Index Co., Ltd. jointly announced that they will adjust the sample stocks of the Sci-Tech Innovation 50 and other indices, effective after the market close on March 13, 2026. Among them, Guodun Quantum, China Science and Technology Fei Testing, and China Science and Technology Star Map will be added to the Sci-Tech Innovation 50 Index, while Rejing Biological, Sruixin Materials, and Junshi Biosciences will be added to the Sci-Tech Innovation 100 Index.

Brain-Computer Interface Concepts Rise

In the afternoon, brain-computer interface concepts surged rapidly. By the close, Yingkang Life was up over 12%, BeiYiKang rose over 7%, Chuang Medical increased over 6%, briefly hitting the daily limit, and Sanbo Brain Science rose more than 3%, with a surge of over 12% during the session.

On the news front, recently, the National Medical Products Administration approved the registration application for BoRuiKang Medical Technology (Shanghai) Co., Ltd.'s implantable brain-computer interface hand motor function compensation system, marking the world’s first launch of a brain-computer interface medical device. This signifies that the first invasive brain-computer interface medical device has entered clinical application.

The product includes an implantable brain-computer interface, implantable EEG electrode set, EEG signal transceiver, pneumatic glove device, disposable surgical kit, EEG decoding software, medical testing software, and clinical management software. It is suitable for patients with limb paralysis caused by cervical spinal cord injury, assisting hand grasp function compensation via pneumatic gloves.

CITIC Securities recently pointed out that under the catalysis of “policy + capital + technology,” the commercialization process of domestic brain-computer interfaces is accelerating. It is expected to gradually evolve from “neurorehabilitation” to “cognitive enhancement” and then to the “brain-machine integration” era. Upstream technological bottlenecks are being broken through, midstream progress is advancing in both China and the U.S., and downstream prospects are vast. The investment can be summarized into three main lines: 1. Leading companies with breakthroughs or excellent clinical results in invasive fields; 2. Leading companies with diversified application scenarios and strong commercialization capabilities in non-invasive fields; 3. Leading companies with advanced CDMO/CRO capabilities.

Jinniu Chemical Hits New Highs Again

Jinniu Chemical (600722) hit the daily limit-up again today, continuing to reach new highs. The stock has now increased limit-ups for three consecutive trading days and has gained six limit-ups in the past ten days, with a total increase of over 80%.

The company announced on the evening of the 12th that its stock price had deviated by more than 20% over two consecutive trading days, with significant volatility. Investors are advised to be cautious of trading risks, make rational decisions, and invest prudently.

The company stated that recently, due to geopolitical factors and other influences, international energy prices have fluctuated, and the supply situation of chemicals like methanol may change, leading to short-term price volatility. Currently, the company’s operations are normal, and there have been no major policy adjustments in the industry. The company has not found any recent media reports or market rumors that could impact its stock price, nor has it been involved in hot concept topics. Additionally, in the first three quarters of 2025, the company achieved a net profit attributable to shareholders of 36.02 million yuan, a decrease of 7.52% compared to 38.96 million yuan in the same period of 2024.

(Source: Securities Times)